A crucial step has been mane in the development of malaria vaccines. T
he first trial of SPf66 in Africa and the first outside Latin America
has been completed in an area of very intense and perennial transmissi
on. In this review, Marcel Tanner, Thomas Teuscher and Pedro Alonso br
iefly discuss the success and the limitations of SPf66, the questions
which remain open and the prospects for further development and applic
ation.